Endo Pharmaceuticals and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin™. The trial is a randomized, active-controlled, open-label, multi-center study with a blinded endpoint assessment designed to compare Urocidin™ with mitomycin C in the intravesical treatment of patients with BCG recurrent or refractory non-muscle-invasive bladder cancer.
It is estimated that 450 patients will be enrolled for this new trial at approximately 120 clinical sites worldwide.
Obesity crisis in the U.S. expected to worsen by 2050